Margarita Salcedo‐Magguilli
Publications by Year
Research Areas
Inflammation biomarkers and pathways, Sepsis Diagnosis and Treatment, Intensive Care Unit Cognitive Disorders, Mosquito-borne diseases and control, Kawasaki Disease and Coronary Complications
Most-Cited Works
- → sTREM-1 is a specific biomarker of TREM-1 pathway activation(2021)71 cited
- → Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial(2020)70 cited
- → Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial(2023)65 cited
- → A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition(2018)44 cited
- → Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial(2021)20 cited
- → Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial(2023)16 cited
- → Identification of the biomarker soluble TREM-1 as a candidate for a personalised medicine approach for nangibotide treatment of septic shock(2022)1 cited
- Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronovirus infection(2020)